Saluk J, Bijak M, Nowak P, Wachowicz B. Evaluating the antioxidative activity of diselenide containing compounds in human blood.
Bioorg Chem 2013;
50:26-33. [PMID:
23941993 DOI:
10.1016/j.bioorg.2013.07.003]
[Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/18/2013] [Accepted: 07/19/2013] [Indexed: 01/17/2023]
Abstract
This study was designed to determine and compare the antioxidant effects of synthetic organoselenium compounds. In experimental trials three different diselenides were used: bis(2-hydroxyphenyl) diselenide, bis{[2-(4-hydroxybenzyl)imino]phenyl} diselenide and bis[2-(4-methylphenylsulfonylamino)phenyl] diselenide. The compounds were screened for antioxidant activities in human blood under oxidation stress conditions. Oxidative stress was induced in vitro in human blood platelet samples and in plasma by 0.1 mM peroxynitrite (ONOO(-)) or by Fe(2+). In experimental trials the levels of chosen oxidative stress markers (TBARS, O2(-), and protein carbonyl groups) were significantly decreased by the action of the tested compounds. The antioxidative properties and the changes in proteins and lipids in the presence of new synthesized selenoorganic compounds were studied in vitro and compared with activity of ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one)--a classical antioxidant, well known as the most important glutathione peroxidase mimetic agent. Our results indicate that the tested diselenides have distinctly protective effects against oxidative alterations of biomolecules caused by ONOO(-) and Fe(2+) in blood platelets and in plasma. Therefore it seems that not only ebselen with a wide spectrum of therapeutic actions but also other organoselenium compounds can be considered in the future as active pharmacological agents.
Collapse